
Opinion|Videos|May 15, 2024
Key Findings from MAJIC-PV
A comprehensive overview of key findings from the MAJIC-PV trial investigating ruxolitinib in patients with polycythemia vera, highlighting efficacy and symptom improvement.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
4
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
5

























